Literature DB >> 24203585

Pelvic exenteration for the treatment of locally advanced colorectal and bladder malignancies in the modern era.

Paul J Speicher1, Ryan S Turley, Jason L Sloane, Christopher R Mantyh, John Migaly.   

Abstract

BACKGROUND: Although pelvic exenteration (PE) remains an important treatment for advanced pelvic malignancies, it has historically been associated with high morbidity and mortality with unclear long-term benefits. The objectives of this study were (1) estimate complication and mortality rates, (2) determine predictors of complications, and (3) estimate overall survival after PE for patients with locally advanced colorectal and bladder tumors.
METHODS: A total of 377 patients were retrospectively identified from the 2005-2010 NSQIP PUF and an additional 1,111 from the 2004-2010 Surveillance Epidemiology and End Results database with T4M0 colorectal or bladder cancers. A logistic regression model was fitted to estimate early morbidity and mortality. The Kaplan-Meier method was used to estimate survival after PE compared to nonoperative management.
RESULTS: Fifty-seven percent of patients had a complication, but 30-day mortality was only 2%. Patients with preoperative dyspnea and higher ASA class had the highest risk of morbidity. PE for the treatment of T4M0 rectal and bladder cancer was associated with significantly improved long-term survival compared to nonoperative therapy.
CONCLUSIONS: PE is associated with a high complication rate but low 30-day mortality. The results of this study provide strong evidence to support PE as a viable treatment option for locally advanced rectal and bladder malignancies in appropriately selected patients.

Entities:  

Mesh:

Year:  2013        PMID: 24203585     DOI: 10.1007/s11605-013-2400-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  21 in total

1.  Contemporary outcomes of total pelvic exenteration in the treatment of colorectal cancer.

Authors:  Ramon E Jimenez; Margo Shoup; Alfred M Cohen; Philip B Paty; Jose Guillem; W Douglas Wong
Journal:  Dis Colon Rectum       Date:  2003-12       Impact factor: 4.585

2.  Late results of bladder substitution with isolated ileal segments.

Authors:  E M BRICKER; H BUTCHER; C A McAFEE
Journal:  Surg Gynecol Obstet       Date:  1954-10

3.  Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy.

Authors:  A BRUNSCHWIG
Journal:  Cancer       Date:  1948-07       Impact factor: 6.860

Review 4.  Management of recurrent cervical cancer: a review of the literature.

Authors:  M Peiretti; I Zapardiel; V Zanagnolo; F Landoni; C P Morrow; A Maggioni
Journal:  Surg Oncol       Date:  2012-01-14       Impact factor: 3.279

5.  Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum.

Authors:  E Rullier; B Goffre; C Bonnel; F Zerbib; M Caudry; J Saric
Journal:  Ann Surg       Date:  2001-11       Impact factor: 12.969

6.  Venous thromboembolism after hepatic resection: analysis of 5,706 patients.

Authors:  Ryan S Turley; Srinevas K Reddy; Cynthia K Shortell; Bryan M Clary; John E Scarborough
Journal:  J Gastrointest Surg       Date:  2012-06-30       Impact factor: 3.452

7.  Complications of pelvic exenteration.

Authors:  J G Jakowatz; D Porudominsky; D U Riihimaki; M Kemeny; W A Kokal; P S Braly; J J Terz; J D Beatty
Journal:  Arch Surg       Date:  1985-11

8.  Curative surgery for local pelvic recurrence of rectal cancer.

Authors:  Norio Saito; Keiji Koda; Nobuhiro Takiguchi; Kenji Oda; Masato Ono; Masanori Sugito; Kiyotaka Kawashima; Masaaki Ito
Journal:  Dig Surg       Date:  2003       Impact factor: 2.588

9.  Primary pelvic exenteration in cervical cancer patients.

Authors:  Laszlo Ungar; Laszlo Palfalvi; Zoltan Novak
Journal:  Gynecol Oncol       Date:  2008-09-05       Impact factor: 5.482

10.  Total pelvic exenteration for primary and recurrent malignancies.

Authors:  F T J Ferenschild; M Vermaas; C Verhoef; A C Ansink; W J Kirkels; A M M Eggermont; J H W de Wilt
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

View more
  4 in total

1.  Factors affecting hospital length of stay following pelvic exenteration surgery.

Authors:  Ying Guo; Eugene Chang; Mehtap Bozkurt; Minjeong Park; Diane Liu; Jack B Fu
Journal:  J Surg Oncol       Date:  2017-10-16       Impact factor: 3.454

2.  Initial experience of laparoscopic pelvic exenteration and comparison with conventional open surgery.

Authors:  Keisuke Uehara; Hayato Nakamura; Yasushi Yoshino; Atsuki Arimoto; Takehiro Kato; Yukihiro Yokoyama; Tomoki Ebata; Masato Nagino
Journal:  Surg Endosc       Date:  2015-03-21       Impact factor: 4.584

3.  Total pelvic exenterative surgery in patients with peritoneal metastases from appendiceal neoplasms. A case series of 2 patients.

Authors:  Paul H Sugarbaker
Journal:  Int J Surg Case Rep       Date:  2019-11-05

4.  Donor Site Morbidity of Patients Receiving Vertical Rectus Abdominis Myocutaneous Flap for Perineal, Vaginal or Inguinal Reconstruction.

Authors:  Vera S Schellerer; Lenka Bartholomé; Melanie C Langheinrich; Robert Grützmann; Raymund E Horch; Susanne Merkel; Klaus Weber
Journal:  World J Surg       Date:  2020-09-29       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.